Xeris Biopharma stock gains on higher targets and August results
Published on 09/19/2026 at 16:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Xeris Biopharma (NASDAQ: XERS) stock is supported by a higher target after Leerink Partners lifted its price view from USD 12.00 to USD 16.00 on September 10, 2026, while the company's August 6, 2026 quarterly results showed revenue of USD 92.1 million and EPS of minus USD 0.18.
Higher targets set the tone
According to MarketBeat on September 19, 2026, Leerink Partners increased its target price on Xeris Biopharma from USD 12.00 to USD 16.00 and kept an outperform rating. The same update said Barclays raised its target from USD 9.00 to USD 12.00 and assigned an overweight rating on August 20, 2026.
That leaves XERS with a MarketBeat consensus rating of Hold and a consensus target of USD 12.80, which sits below Leerink's new USD 16.00 view. Four analysts rate the stock Buy, two Hold and one Sell, a split that shows why the name still attracts active research coverage.
August numbers still matter
MarketBeat also said Xeris Biopharma last reported earnings on August 6, 2026, with EPS of minus USD 0.18, missing the consensus estimate of USD 0.01 by USD 0.19. Revenue for the quarter came in at USD 92.1 million, above the USD 90.12 million estimate.
The same report put the company's return on equity at 338.21 percent and net margin at minus 5.12 percent. For investors, that mix matters more than the headline revenue beat: the business is still posting a loss, but the top line is running ahead of expectations.
Stock range stays wide
MarketBeat's September 19, 2026 update also put Xeris Biopharma's 52-week range at USD 5.25 to USD 10.08. The share price was not included in the available market snapshot, but the range still shows the stock trading inside a narrow band around recent analyst revisions.
As of September 19, 2026, XERS is still defined by that gap between improving analyst targets and a loss-making quarter, with the next move likely to be shaped by whether the company can keep revenue ahead of estimates. The latest visible market marker remains the 52-week range of USD 5.25 to USD 10.08.
Xeris Biopharma stock at a glance
- Company: Xeris Biopharma Holdings, Inc.
- ISIN: US98422E1038
- Ticker: XERS
- Trading venue: NASDAQ
- Market capitalization: USD 5.25 to USD 10.08 52-week range (as of September 19, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Not stated in the available market snapshot
